Plain-English translation of NCT06105554 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called for people with multiple myeloma—a blood cancer—that has come back or stopped responding to previous treatments. The study has two parts: first, researchers will find the safest and most effective dose of the medication alone, and then they will test whether the medication works better when combined with a steroid called dexamethasone. The goal is to see if this treatment can help shrink or control the cancer in people who have already tried at least three other types of therapy.
Multiple myeloma can become resistant to standard treatments, leaving patients with limited options. This trial exists to find a new treatment approach for people whose cancer no longer responds to the usual medications, potentially offering them another chance at controlling their disease.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the medication by mouth (as a pill) at doses determined by the study phase you enter. You will need to visit the hospital regularly for blood tests, physical exams, and imaging scans to monitor how your body is responding and check for side effects. The study will likely last several months, and during that time researchers will carefully track whether your myeloma is improving and how well you tolerate the treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States